GPT and non-alcoholic fatty liver: Mono (Trulicity and euk21) and dual (L21 and D21) agonist treatment significantly reduced liver levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST) and alkaline phosphatase (ALP), as well as blood levels of ALT and ALP (Supplementary Figure S2A) and nonalcoholic fatty liver score (NAS) and fibrosis score (Supplementary Figure S2B).